How much do patients need to pay after Belumosudil is reimbursed?

Belumosudil mesylate tablets (Belumosudil) are currently on the market in China and are included in the National Medical Insurance List for the treatment of chronic graft-versus-host disease (cGVHD). This means that patients who meet the medical insurance indications can enjoy partial reimbursement policies after using the drug in regular hospitals, thus significantly reducing out-of-pocket expenses. The original drug of Besudil is expensive overseas, and the market price per box (0.2g*30 tablets) can be as high as 10,000 to 20,000 yuan. However, the medical insurance negotiations after the domestic launch have significantly reduced the burden on patients.

Depending on the reimbursement ratio of medical insurance in different regions, the patient's out-of-pocket amount after reimbursement may fluctuate between 10% and 30% of the drug price. Taking some provinces and cities as an example, the out-of-pocket price per box after medical insurance reimbursement may be around several thousand yuan. The specific amount is also related to the type of medical insurance, personal account payment ratio and hospital grade. For patients who have been included in the coverage of major diseases, the reimbursement ratio is usually higher, even reaching 70% to 90%. In addition, some areas have also established charitable assistance or patient support programs to provide free or reduced-cost drugs to eligible patients to further reduce the financial burden.

Besudil is an innovative drug aimed at rebuilding the immune system. Its high cost is mainly due to the complex research and development process and clinical trial investment. After being included in medical insurance, it not only improves drug accessibility, but also enables more patients with cGVHD to obtain long-term treatment opportunities. It is worth noting that medical insurance reimbursement usually requires meeting specific diagnostic standards and being used in designated hospitals. Patients should consult the attending doctor or local medical insurance agency to understand the specific reimbursement ratio and application process. Overall, after being covered by medical insurance, the out-of-pocket pressure of besudil has been significantly reduced, providing more sustainable economic support for the long-term management of chronic graft-versus-host disease.

Reference: https://www.drugs.com/pro/rezurock.html